We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
(+27%)
Cap. Flow
+$9.92M
Cap. Flow
% of AUM
0.69%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Avg Time Held Equity + Options
2.9
quarters
Top 10 Avg Time Held Equity + Options
4.7
quarters
Top 20 Avg Time Held Equity + Options
4.1
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
4.7
quarters
Top 20 Avg Time Held Equity only
4.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXTM
NxStage Medical Inc.
NXTM
|
+$24.7M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$23.8M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$18.4M |
| 4 |
STJ
St Jude Medical
STJ
|
+$16.6M |
| 5 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$41.5M |
| 2 |
Humana
HUM
|
+$20.1M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$12.4M |
| 4 |
Baxter International
BAX
|
+$9.04M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$6.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.68% |
| 2 | Miscellaneous | 20.64% |
| 3 | Consumer Staples | 0.52% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
GNCA
151
DELISTED
Genocea Biosciences, Inc.
GNCA
| $71K | ﹤0.01% |
2,164
-62,413
| -97% | -$2.29M |
2016 Q1
1 quarter
|
|
|
AIMT
152
DELISTED
Aimmune Therapeutics
AIMT
| $70K | ﹤0.01% |
+6,448
| New | +$87.6K |
2016 Q2
0 quarters
|
|
153
Corcept Therapeutics
CORT
$12.7B
| $60K | ﹤0.01% |
+11,000
| New | +$57.2K |
2016 Q2
0 quarters
|
|
|
AVXS
154
DELISTED
AveXis, Inc. Common Stock
AVXS
| $58K | ﹤0.01% |
1,515
-148,485
| -99% | -$5.02M |
2016 Q1
1 quarter
|
|
155
Atara Biotherapeutics
ATRA
$93.1M
| $56K | ﹤0.01% |
+100
| New | +$48K |
2016 Q2
0 quarters
|
|
156
Seres Therapeutics
MCRB
$25.7M
| $45K | ﹤0.01% |
+77
| New | +$45.2K |
2016 Q2
0 quarters
|
|
|
JUNO
157
DELISTED
Juno Therapeutics, Inc.
JUNO
| $43K | ﹤0.01% |
+1,113
| New | +$46.2K |
2016 Q2
0 quarters
|
|
158
DELISTED
Dynavax Technologies
DVAX
| $36K | ﹤0.01% |
+2,499
| New | +$42.7K |
2016 Q2
0 quarters
|
|
159
Lineage Cell Therapeutics
LCTX
$229M
| $36K | ﹤0.01% |
+15,705
| New | +$38.5K |
2016 Q2
0 quarters
|
|
160
Capricor Therapeutics
CAPR
$405M
| $16K | ﹤0.01% |
400
| – | – |
2015 Q1
5 quarters
|
|
161
DELISTED
Avinger, Inc. Common Stock
AVGR
| – | – |
0
| – | – |
2016 Q1
1 quarter
|
|
162
Glaukos
GKOS
$9.77B
| $9K | ﹤0.01% |
+300
| New | +$6.94K |
2016 Q2
0 quarters
|
|
163
Voyager Therapeutics
VYGR
$134M
| $7K | ﹤0.01% |
+650
| New | +$7.95K |
2016 Q2
0 quarters
|
|
164
Inogen
INGN
$168M
| $6K | ﹤0.01% |
125
| – | – |
2015 Q4
2 quarters
|
|
165
Alaunos Therapeutics
TCRT
$8.54M
| $5K | ﹤0.01% |
+7
| New | +$7.62K |
2016 Q2
0 quarters
|
|
166
Decoy Therapeutics
DCOY
$839K
| – | – |
0
| – | – |
2015 Q4
2 quarters
|
|
|
TNGN
167
DELISTED
TENGION INC COM NEW STK (DE)
TNGN
| $1K | ﹤0.01% |
+1,826,399
| New | +$1K |
2016 Q2
0 quarters
|
|
168
PUT
Acadia Pharmaceuticals
ACAD
$3.21B
| – | – |
-200,000
| Closed | -$2.8M | – |
|
169
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-2,000
| Closed | -$103K | – |
|
170
DELISTED
Amedisys
AMED
| – | – |
-10,493
| Closed | -$507K | – |
|
171
Amgen
AMGN
$223B
| – | – |
-30,000
| Closed | -$4.5M | – |
|
172
Apyx Medical
APYX
$108M
| – | – |
-162,700
| Closed | -$272K | – |
|
173
Armata Pharmaceuticals
ARMP
$113M
| – | – |
-571
| Closed | -$315K | – |
|
|
174
CALL
Baxter International
BAX
$12.9B
| – | – |
-175,400
| Closed | -$7.17M | – |
|
|
175
Baxter International
BAX
$12.9B
| – | – |
-220,000
| Closed | -$9.04M | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2016 Portfolio in Review
As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors's Q2 2016 filing shows 57 new, 37 increased, 31 reduced and 55 closed positions. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M. The largest sale was Allergan plc, an estimated $41.5M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
- Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
- Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
- Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
- Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
- Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
- Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.
Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.